{
    "root": "30168ea9-9be5-75bd-e063-6394a90ab409",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Famotidine",
    "value": "20250311",
    "ingredients": [
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FAMOTIDINE",
            "code": "5QZO15J2Z8",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4975"
        }
    ],
    "indications": {
        "text": "famotidine tablets indicated adult pediatric patients 40 kg greater treatment : \u2022 active duodenal ulcer ( du ) . \u2022 active gastric ulcer ( gu ) . \u2022 symptomatic nonerosive gastroesophageal reflux disease ( gerd ) . \u2022 erosive esophagitis due gerd , diagnosed biopsy . famotidine tablets indicated adults : \u2022 treatment pathological hypersecretory conditions ( e.g . , zollinger-ellison syndrome , multiple endocrine neoplasias ) . \u2022 reduction risk duodenal ulcer recurrence .",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "gastric ulcer (DOID:10808)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10808"
            },
            {
                "text": "gastroesophageal reflux (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            },
            {
                "text": "zollinger-ellison syndrome (DOID:0050782)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050782"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "zollinger-ellison syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_913"
            }
        ]
    },
    "contraindications": {
        "text": "indication recommended ( 2.1 ) adult pediatric patients 40 kg greater active du 40 mg daily ; 20 mg twice daily active gastriculcer 40 mg daily gerd 20 mg twice daily erosive esophagitis 20 mg twice daily ; or40 mg twice daily adults pathological hypersecretory conditions 20 mg every 6 hours ; adjust patient needs ; maximum 160 mg every 6 hours risk reduction du recurrence 20 mg daily \u2022 full prescribing information complete dosing information , including dosing renal impairment , recommended treatment duration . ( 2.1 , 2.2 ) ( 2.3 ) : take daily bedtime twice daily morning bedtime without food .",
        "doid_entities": [
            {
                "text": "gerd (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "famotidine tablets usp , 20 mg yellow , film-coated , round shaped tablets \u2018 c \u2019 119 one side plain side supplied bottles 60 's counts - ndc 68645-594-59. storage store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) [ usp controlled room temperature ] . dispense usp tight , light-resistant container .",
    "adverseReactions": "famotidine tablets contraindicated patients history serious hypersensitivity ( e.g . , anaphylaxis ) famotidine histamine-2 ( h 2 ) receptor antagonists .",
    "indications_original": "Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of:\n                  \u2022 active duodenal ulcer\u00a0(DU).\n                  \u2022 active gastric ulcer (GU).\n                  \u2022 symptomatic nonerosive gastroesophageal reflux disease (GERD).\n                  \u2022 erosive esophagitis due to GERD, diagnosed by biopsy. \n                  Famotidine tablets are indicated in adults for the:\n                  \u2022 treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).\n                  \u2022 reduction of the risk of duodenal ulcer\u00a0recurrence.",
    "contraindications_original": "Indication Recommended Dosage\u00a0( 2.1 ) Adult and\u00a0Pediatric\u00a0Patients 40 kg and greater Active DU 40 mg once daily; or 20 mg twice\u00a0daily Active\u00a0GastricUlcer 40 mg once\u00a0daily GERD 20 mg twice daily Erosive Esophagitis 20 mg twice daily; or40 mg twice daily Adults Pathological Hypersecretory Conditions 20 mg every 6 hours; adjust to patient needs; maximum 160 mg every 6\u00a0hours Risk Reduction of DU Recurrence 20 mg once daily \u2022 See full prescribing information for complete dosing information, including dosing in renal impairment, and recommended treatment duration. ( 2.1 , 2.2 ) Administration ( 2.3 ): Take once daily before bedtime or twice daily in the morning and before bedtime with or without\u00a0food.",
    "warningsAndPrecautions_original": "Famotidine tablets USP, 20 mg are yellow, film-coated, round shaped tablets with \u2018C\u2019\n                  119\n                  on one side and plain on other side and are supplied in bottles of 60's counts - NDC 68645-594-59.\n                  \n                  \n                     Storage\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F) [see USP Controlled Room Temperature].\n                  Dispense in a USP tight, light-resistant container.",
    "adverseReactions_original": "Famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (H\n       \n \n  2) receptor antagonists.",
    "drug": [
        {
            "name": "Famotidine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4975"
        }
    ]
}